Connect Biopharma Holdings Stock Buy Hold or Sell Recommendation
| CNTB Stock | USD 1.02 0.01 0.97% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Connect Biopharma Holdings is 'Strong Sell'. Macroaxis provides Connect Biopharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CNTB positions.
Check out Connect Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Connect and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Connect Biopharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Connect |
Execute Connect Biopharma Buy or Sell Advice
The Connect recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Connect Biopharma Holdings. Macroaxis does not own or have any residual interests in Connect Biopharma Holdings or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Connect Biopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Very regressive towards the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Connect Biopharma Trading Alerts and Improvement Suggestions
| Connect Biopharma generated a negative expected return over the last 90 days | |
| Connect Biopharma has some characteristics of a very speculative penny stock | |
| Connect Biopharma has high historical volatility and very poor performance | |
| Net Loss for the year was (59.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Connect Biopharma Holdings currently holds about 1.28 B in cash with (47.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 41.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: CNTB Stock Surges Amid Positive Earnings and Strong Buy Ratings |
Connect Biopharma current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Connect analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Connect analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Connect Biopharma Returns Distribution Density
The distribution of Connect Biopharma's historical returns is an attempt to chart the uncertainty of Connect Biopharma's future price movements. The chart of the probability distribution of Connect Biopharma daily returns describes the distribution of returns around its average expected value. We use Connect Biopharma Holdings price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Connect Biopharma returns is essential to provide solid investment advice for Connect Biopharma.
| Mean Return | 0.29 | Value At Risk | -9.01 | Potential Upside | 12.12 | Standard Deviation | 7.21 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Connect Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Connect Stock Institutional Investors
| Shares | Qube Research & Technologies | 2024-06-30 | 46.0 | Fidelity Management And Research Company | 2024-06-30 | 0.0 | Two Sigma Investments Llc | 2024-06-30 | 0.0 | Bml Capital Management Llc | 2024-09-30 | 2.1 M | Ubs O'connor Llc | 2024-09-30 | 510.7 K | Renaissance Technologies Corp | 2024-09-30 | 175.5 K | Blackrock Inc | 2024-06-30 | 103.9 K | Keudell/morrison Wealth Management | 2024-09-30 | 33.5 K | Geode Capital Management, Llc | 2024-09-30 | 28 K | Commonwealth Equity Services Inc | 2024-06-30 | 20 K | Royal Bank Of Canada | 2024-06-30 | 12.7 K |
Connect Biopharma Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (2.3M) | 18.2M | 13.5M | (571.3M) | 75.2M | 78.9M | |
| Change In Cash | (92.6M) | 107.4M | 696.8M | (168.9M) | 27.0M | 25.6M | |
| Depreciation | 790K | 221.1K | 4.1M | 1.0M | 988K | 1.4M | |
| Capital Expenditures | 1.1M | 2.3M | 47.5M | 4.3M | 294K | 279.3K | |
| Net Income | (168.6M) | (119.4M) | (1.3B) | (116.1M) | (59.4M) | (62.4M) | |
| End Period Cash Flow | 309.0M | 154.7M | 1.7B | 80.4M | 106.0M | 100.7M |
Connect Biopharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Connect Biopharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Connect Biopharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Connect stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.06 | |
β | Beta against Dow Jones | 1.92 | |
σ | Overall volatility | 4.92 | |
Ir | Information ratio | 0.02 |
Connect Biopharma Volatility Alert
Connect Biopharma Holdings is displaying above-average volatility over the selected time horizon. Connect Biopharma Holdings is a potential penny stock. Although Connect Biopharma may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Connect Biopharma Holdings. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Connect instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Connect Biopharma Fundamentals Vs Peers
Comparing Connect Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Connect Biopharma's direct or indirect competition across all of the common fundamentals between Connect Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Connect Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Connect Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Connect Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Connect Biopharma to competition |
| Fundamentals | Connect Biopharma | Peer Average |
| Return On Equity | -0.18 | -0.31 |
| Return On Asset | -0.12 | -0.14 |
| Profit Margin | (0.89) % | (1.27) % |
| Operating Margin | 0.25 % | (5.51) % |
| Current Valuation | (52.94 M) | 16.62 B |
| Shares Outstanding | 55.25 M | 571.82 M |
| Shares Owned By Insiders | 41.16 % | 10.09 % |
| Shares Owned By Institutions | 44.42 % | 39.21 % |
| Number Of Shares Shorted | 61.79 K | 4.71 M |
| Price To Book | 0.52 X | 9.51 X |
| Price To Sales | 2.36 X | 11.42 X |
| EBITDA | (58.37 M) | 3.9 B |
| Net Income | (59.38 M) | 570.98 M |
| Cash And Equivalents | 1.28 B | 2.7 B |
| Cash Per Share | 23.26 X | 5.01 X |
| Total Debt | 465 K | 5.32 B |
| Debt To Equity | 0 % | 48.70 % |
| Current Ratio | 9.58 X | 2.16 X |
| Book Value Per Share | 2.00 X | 1.93 K |
| Cash Flow From Operations | (47.93 M) | 971.22 M |
| Short Ratio | 2.41 X | 4.00 X |
| Earnings Per Share | (0.39) X | 3.12 X |
| Target Price | 7.0 | |
| Number Of Employees | 81 | 18.84 K |
| Beta | -0.31 | -0.15 |
| Market Capitalization | 56.91 M | 19.03 B |
| Total Asset | 125.89 M | 29.47 B |
| Retained Earnings | (539.35 M) | 9.33 B |
| Working Capital | 96.71 M | 1.48 B |
| Net Asset | 125.89 M |
Connect Biopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Connect . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Connect Biopharma Buy or Sell Advice
When is the right time to buy or sell Connect Biopharma Holdings? Buying financial instruments such as Connect Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Connect Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Discretionary ETFs Thematic Idea Now
Consumer Discretionary ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Consumer Discretionary ETFs theme has 29 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Discretionary ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Connect Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.39) | Revenue Per Share 0.438 | Return On Assets (0.12) | Return On Equity (0.18) |
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.